Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.23
-26.8%
$0.25
$0.17
$3.93
$743K-0.08130,410 shs20,702 shs
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.15
+6.5%
$0.14
$0.15
$7.90
$660K1.1281,791 shs16,292 shs
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
$1.16
$0.16
$3.32
$330K1.6611,347 shs107,749 shs
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$3.64
-2.7%
$4.43
$2.51
$2,465.94
$157K1.43176,166 shs7,950 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00%-9.54%+16.24%-6.72%-93.01%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%+4.21%+16.72%-97.79%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00%0.00%0.00%0.00%-91.29%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
-2.67%-4.71%-11.44%+3.12%-99.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
2.1305 of 5 stars
0.04.00.04.60.90.01.9
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1.8931 of 5 stars
3.50.00.00.00.02.50.6
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
3.00
Buy$23.0015,664.22% Upside
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00
N/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$892K0.74N/AN/A($36.43) per share0.00
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/A($8.29) per shareN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$19.29M0.01N/AN/A$163.50 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$7.490.01N/AN/A-471.57%-296.50%8/7/2025 (Estimated)
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%8/11/2025 (Estimated)
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
-$6.16MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/A
0.05
0.05
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/A
0.16
0.22
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
43.74%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
10.91%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.18%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
51.08%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
20.59%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
57.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1204.52 million2.21 millionOptionable
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
601.57 million1.22 millionNot Optionable
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
22043,000731,000Not Optionable

Recent News About These Companies

UPC’s Unexpected Plunge: What’s Next?
Universe Pharmaceuticals gets Nasdaq delisting notice
Universe Pharmaceuticals Files Registration for 37.5 Million Shares

New MarketBeat Followers Over Time

Top Headlines

View All Headlines
Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.23 -0.09 (-26.82%)
As of 07/8/2025 03:15 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Biora Therapeutics stock logo

Biora Therapeutics NASDAQ:BIOR

$0.15 +0.01 (+6.50%)
As of 06/13/2025

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Kiromic BioPharma stock logo

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Universe Pharmaceuticals stock logo

Universe Pharmaceuticals NYSE:UPC

$3.64 -0.10 (-2.67%)
Closing price 07/9/2025 03:59 PM Eastern
Extended Trading
$3.70 +0.05 (+1.51%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.